
FDA Grants Priority Review to TAR-200 for Bladder Cancer Subset
The U.S. Food and Drug Administration (FDA) has granted priority review to the new drug application for TAR-200, a gemcitabine-releasing intravesical system, for patients with high-risk non-muscle invasive bladder cancer that is unresponsive to Bacillus …